These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 4125022)
41. Delayed cutaneous sensitivity reactions to extracts of autologous malignant melanoma: a second look. Bluming AZ; Vogel CL; Ziegler JL; Kiryabwire JW J Natl Cancer Inst; 1972 Jan; 48(1):17-24. PubMed ID: 4652371 [No Abstract] [Full Text] [Related]
42. Development of chronic lymphocytic leukaemia during ipilimumab therapy in a patient with metastatic melanoma. Arenbergerova M; Fialova A; Gkalpakiotis S; Kodet R; Jancarkova T; Novotna M; Hess A; Puzanov I; Arenberger P J Eur Acad Dermatol Venereol; 2016 Sep; 30(9):1626-7. PubMed ID: 26275120 [No Abstract] [Full Text] [Related]
43. Chemotherapy of melanoma. Luce JK Semin Oncol; 1975 Jun; 2(2):179-85. PubMed ID: 1234375 [No Abstract] [Full Text] [Related]
44. Comparative evaluation of three combination regimens for advanced malignant melanoma: results of an international cooperative study. Beretta G; Bonadonna G; Cascinelli N; Morabito A; Veronesi U Cancer Treat Rep; 1976 Jan; 60(1):33-40. PubMed ID: 1000518 [TBL] [Abstract][Full Text] [Related]
50. Treatment of advanced malignant melanoma with vinblastine, bleomycin, and cisplatin. Bajetta E; Rovej R; Buzzoni R; Vaglini M; Bonadonna G Cancer Treat Rep; 1982 Jun; 66(6):1299-302. PubMed ID: 6177408 [TBL] [Abstract][Full Text] [Related]
51. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950 [TBL] [Abstract][Full Text] [Related]
52. Upregulation of granzyme B and interferon-γ mRNA in responding lesions by treatment with nivolumab for metastatic melanoma: a case report. Anegawa H; Otsuka A; Kaku Y; Nonomura Y; Fujisawa A; Endo Y; Kabashima K J Eur Acad Dermatol Venereol; 2016 Dec; 30(12):e231-e232. PubMed ID: 26837059 [No Abstract] [Full Text] [Related]
53. 18F-FDG PET/CT Reveals Disease Remission in a Patient With Ipilimumab-Refractory Advanced Melanoma Treated With Pembrolizumab. Sachpekidis C; Hassel JC; Dimitrakopoulou-Strauss A Clin Nucl Med; 2016 Feb; 41(2):156-8. PubMed ID: 26545022 [TBL] [Abstract][Full Text] [Related]
54. Changing Treatment Paradigms for Brain Metastases From Melanoma-Part 2: When and How to Use the New Systemic Agents. Venur VA; Funchain P; Kotecha R; Chao ST; Ahluwalia MS Oncology (Williston Park); 2017 Sep; 31(9):659-67. PubMed ID: 29071693 [TBL] [Abstract][Full Text] [Related]
57. Current management of melanoma. Seigler HF; Fetter BF Ann Surg; 1977 Jul; 186(1):1-12. PubMed ID: 327949 [No Abstract] [Full Text] [Related]
58. [ASCO highlights in the treatment of metastatic melanoma]. Hertlein A Med Monatsschr Pharm; 2014 May; 37(5):183-4. PubMed ID: 24908933 [No Abstract] [Full Text] [Related]
59. [Treatment of cutaneous and cutaneously metastasizing malignant neoplasms using massive doses of antineoplastic agents]. Denk R; Gebhardt R Hautarzt; 1972 Aug; 23(8):354-7. PubMed ID: 4638949 [No Abstract] [Full Text] [Related]
60. Advances in the management of melanoma: targeted therapy, immunotherapy and future directions. Dean E; Lorigan P Expert Rev Anticancer Ther; 2012 Nov; 12(11):1437-48. PubMed ID: 23249108 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]